Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
229 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06607289 | National Longitudinal Cohort of Hematological Diseases (NICHE) - CART | recruiting | — | 1,000 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT06996132 | Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma | recruiting | Phase 2 | 25 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 17, 2025 |
| clinicaltrials |
| NCT07019766 | National Longitudinal Cohort of Hematological Diseases-Large Granular Lymphocytic Leukemia(NICHE-LGLL) | recruiting | — | 9,999 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT02975687 | CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia | completed | Phase 1 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT04034446 | CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL) | terminated | Early Phase 1 | 2 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT04415008 | Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid Leukemia | active not recruiting | Phase 2 | 61 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT05292898 | A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia | terminated | Phase 1 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT05318963 | Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma | terminated | Phase 1 | 14 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT05594784 | Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL | completed | Phase 2 | 79 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT05941585 | Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid Leukemia | completed | N/A | 60 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT06770257 | Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive Chemotherapy | withdrawn | Phase 2 | 0 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jun 3, 2025 | clinicaltrials |
| NCT06880354 | A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 37 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT02267993 | Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients | completed | Phase 4 | 58 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT02937662 | Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML | completed | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT03031249 | Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia | enrolling by invitation | Phase 1 / Phase 2 | 80 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT03031262 | Efficacy and Safety of Chidamide in CBF Leukemia | active not recruiting | Phase 1 / Phase 2 | 250 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT05356169 | Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid Leukemia | active not recruiting | Phase 2 / Phase 3 | 312 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT06449482 | Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy | terminated | Phase 1 / Phase 2 | 6 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT06757855 | Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML | recruiting | Phase 1 / Phase 2 | 29 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT06244368 | GVM±R in Patients With Relapsed or Refractory Aggressive NHL. | recruiting | Phase 2 | 115 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT04690192 | CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma | completed | Phase 1 / Phase 2 | 30 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT05294055 | Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma | recruiting | Phase 2 | 120 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT05299164 | GVM±R in Patients With Relapsed or Refractory Aggressive NHL | active not recruiting | Phase 1 | 18 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT06955858 | Clinical Study of rhTPO in Hematopoietic Stem Cell Mobilization for Autologous Transplantation in Acute Leukemia | not yet recruiting | N/A | 60 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT03560908 | Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation | withdrawn | Phase 1 | 0 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT05071482 | Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL | terminated | Phase 4 | 39 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT06900088 | Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients | not yet recruiting | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT05454241 | CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies | completed | Phase 2 | 14 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT04600960 | Eltrombopag for Chemotherapy-induced Thrombocytopenia | recruiting | Phase 2 | 50 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT05218226 | Avatrombopag for Chemotherapy-induced Thrombocytopenia | unknown | Phase 2 | 50 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT05236582 | Herombopag for Chemotherapy-induced Thrombocytopenia | recruiting | Phase 2 | 50 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT06792630 | A Study of the Effect of Laughter Therapy on the Mental Health and Quality of Survival of Hematopoietic Stem Cell Transplant Patients | not yet recruiting | N/A | 98 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jan 24, 2025 | clinicaltrials |
| NCT06783790 | Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT | recruiting | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06758726 | Mitoxantrone Hydrochloride Liposome Combined With BU/Cy Were Used as a Conditioning Regimen for Patients With Intermediate/Adverse Risk or Persistently Positive MRD AML | not yet recruiting | N/A | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jan 6, 2025 | clinicaltrials |
| NCT05958719 | Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma | recruiting | Phase 2 | 37 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06643195 | Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Re-treatment for Patients With High-Risk Acute Myeloid Leukemia | not yet recruiting | N/A | 358 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06712173 | Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) | not yet recruiting | Phase 1 | 33 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Dec 2, 2024 | clinicaltrials |
| NCT05601466 | Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia | terminated | Phase 1 | 3 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Nov 6, 2024 | clinicaltrials |
| NCT05601830 | Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease | terminated | Phase 1 | 1 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Nov 6, 2024 | clinicaltrials |
| NCT06608732 | Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission. | recruiting | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT06658925 | Olverembatinib as Maintenance Therapy or Preemptive Therapy After Allo-HSCT in Ph+ALL | not yet recruiting | Phase 2 | 50 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Oct 26, 2024 | clinicaltrials |
| NCT06658938 | Blinatumomab as Maintenance Therapy in Patients With High-risk B-lineage Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation | not yet recruiting | N/A | 30 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Oct 26, 2024 | clinicaltrials |
| NCT06613035 | Twice-per-weekSelinexor, 2 Days Melphalan | not yet recruiting | Phase 3 | 126 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT06608342 | Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute Lymphoblastic Leukemia | recruiting | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT06586099 | Tislelizumab with Azacitidine in the Treatment of R/R AML | withdrawn | Phase 1 / Phase 2 | 0 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05914662 | Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM(ZBR) | unknown | Phase 2 | 42 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT06547944 | Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)(ZGR in TN CLL) | active not recruiting | Phase 1 | 30 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06427330 | Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia | unknown | Phase 2 | 21 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT06513234 | Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas | recruiting | Phase 2 | 45 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT06461091 | the Efficacy and Safety of Total Myeloid Irradiation (TMI) in the Treatment of Adult Acute Lymphoblastic Leukemia(TMI) | unknown | — | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jul 11, 2024 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials